The LDHA inhibitor stiropentol has been shown to reduce seizures in preclinical studies and is an FDA approved treatment option for seizure management in Dravet syndrome (Sada et al., 2015; Nickels and Wirrell, 2017) Although LDH inhibition has been proven to reduce tumor growth, its anti-convulsive effects in GRE patients have not yet been explored (Guyon et al., 2022). The gene discussed is LDHA; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.